Evidence map›Paper›PMID 35280939›Full record

ArticlePharmacogenomics and personalized medicine2022

Associations of SMAD4 rs10502913 and NLRP3 rs1539019 Polymorphisms with Risk of Coal Workers' Pneumoconiosis Susceptibility in Chinese Han Population.

Hai Zhao, Yaqiong Huang, Hao Wang, Juan Zhao, Shanshan Tian, Haixia Bai, Mufang Guo, Caiping Dong, Yongliang Shi, Xia Li and 4 more

Open access · goldAbstract read
In one paragraph

Article in Pharmacogenomics and personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Hai Zhao *Department of Pulmonary and Critical Care Medicine, Sinopharm Tongmei General Hospital, Datong, People's Republic of China.
Yaqiong Huang *Department of Pulmonary and Critical Care Medicine, Sinopharm Tongmei General Hospital, Datong, People's Republic of China.
Hao WangSchool of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
Juan ZhaoDepartment of Pulmonary and Critical Care Medicine, Sinopharm Tongmei General Hospital, Datong, People's Republic of China.
Shanshan TianDepartment of Pulmonary and Critical Care Medicine, Sinopharm Tongmei General Hospital, Datong, People's Republic of China.
Haixia BaiDepartment of Pulmonary and Critical Care Medicine, Sinopharm Tongmei General Hospital, Datong, People's Republic of China.
Mufang GuoDepartment of Pulmonary and Critical Care Medicine, Sinopharm Tongmei General Hospital, Datong, People's Republic of China.
Caiping DongDepartment of Pulmonary and Critical Care Medicine, Sinopharm Tongmei General Hospital, Datong, People's Republic of China.
Yongliang ShiDepartment of Pulmonary and Critical Care Medicine, Sinopharm Tongmei General Hospital, Datong, People's Republic of China.
Xia LiDepartment of Pulmonary and Critical Care Medicine, Sinopharm Tongmei General Hospital, Datong, People's Republic of China.
Chengjun ZhuDepartment of Pulmonary and Critical Care Medicine, Sinopharm Tongmei General Hospital, Datong, People's Republic of China.
Tao FengDepartment of Pulmonary and Critical Care Medicine, Sinopharm Tongmei General Hospital, Datong, People's Republic of China.
Xia MaDepartment of Respiratory and Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China.
Zhifei HouDepartment of Pulmonary and Critical Care Medicine, Sinopharm Tongmei General Hospital, Datong, People's Republic of China.ORCID 0000-0003-1674-1666
China National Pharmaceutical Group Corporation (China) · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNBeijing YouAn Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: CWP is an untreatable but preventable fibrotic lung disease caused by the chronic inhalation of coal dust. Genetic factors such as polymorphisms play an important role in the development of CWP. The present study investigated the association between the polymorphisms of SMAD4 and NLRP3 and CWP risk in a Chinese Han population. Patients and Methods: SMAD4 rs10502913 and NLRP3rs1539019 polymorphisms were examined in 292 CWP subjects and 315 coal dust-exposed controls. The genotypes were analyzed using direct sequencing. The allele and genotype proportion between the cases and controls were compared using the chi-square test. Results: The AG and GG genotypes of SMAD4 rs10502913 were not associated with altered CWP risk compared with AA genotype (adjusted OR = 1.535 and 1.426, 95% CI = 0.785-3.000 and 0.732-2.781, Conclusion: In this present study, SMAD4 rs10502913 and NLRP3 rs1539019 genotypes were not associated with altered CWP risk in the Chinese Han population. Large sample sizes and multicenter studies are needed to elucidate these results in the future.

Indexed as

CWPNLRP3 rs1539019polymorphismsSMAD4 rs10502913

Identifiers

PMID35280939
PMCPMC8904432
OpenAlexW4214899377

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.